Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System

NCT02038218 is registered in ClinicalTrials.gov with DEKK-TEC, Inc. as lead sponsor.

NCT NCT02038218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02038218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System
Lead sponsor
DEKK-TEC, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
August 31, 2020
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm to brain, primary brain tumors